Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track

Fineline Cube Feb 27, 2026
Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Fineline Cube Feb 26, 2026
Company Deals

Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility

Fineline Cube Jul 31, 2024

Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...

Company

Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization

Fineline Cube Jul 31, 2024

Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...

Company Drug

Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA

Fineline Cube Jul 31, 2024

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...

Policy / Regulatory

China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies

Fineline Cube Jul 31, 2024

The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...

Company

WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges

Fineline Cube Jul 30, 2024

China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...

Company Deals

Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business

Fineline Cube Jul 30, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...

Company

Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand

Fineline Cube Jul 30, 2024

Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...

Company Deals

GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines

Fineline Cube Jul 30, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...

Company Drug

Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment

Fineline Cube Jul 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors

Fineline Cube Jul 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies

Fineline Cube Jul 30, 2024

Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Medical Device

ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First

Fineline Cube Jul 30, 2024

Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...

Company Deals

Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia

Fineline Cube Jul 30, 2024

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture...

Company Drug

Organon’s Liptruzet Launches in China for Hypercholesterolemia Treatment

Fineline Cube Jul 30, 2024

US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet...

Company Deals

LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline

Fineline Cube Jul 30, 2024

LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...

Company Medical Device

Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device

Fineline Cube Jul 30, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...

Company Deals

Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion

Fineline Cube Jul 30, 2024

Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...

Policy / Regulatory

China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets

Fineline Cube Jul 30, 2024

The Ministry of Industry and Information Technology (MIIT) has released a report on the first...

Policy / Regulatory

China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results

Fineline Cube Jul 30, 2024

The National Health Commission (NHC) of China has released a notice detailing the results of...

Company Drug

EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi

Fineline Cube Jul 29, 2024

Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...

Posts pagination

1 … 283 284 285 … 627

Recent updates

  • BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised
  • FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track
  • WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development
  • MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection
  • SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised

Company Drug

FDA Approves Boehringer’s Zongertinib in Record 44 Days – First Oral HER2 TKI Wins CNPV Fast‑Track

Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Others

MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.